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要　旨
２０１４年に日本で承認された新医療用原薬に対し、安定性試験の現状を調査した。我々は、２０１４年に安
定性試験の記述がある６６の新医療用原薬を特定した。長期保存試験としては、３２原薬が２５±２℃/６０±
５％相対湿度（RH）または３０±２℃/６５±５％RH の条件下で、１４原薬が５±３℃で、２　 原薬が－２０±
５℃で実施されていた。光安定性試験では、２２原薬が安定で、２４原薬が光不安定であり、不明のものが
２２原薬であった。光安定性試験で不安定であった原薬は、すべて遮光保存とされた。これらのことから、
２０１４年に承認された新医療用原薬は、ICH ガイドラインに従って、適切に設定されていることがわかっ
た。
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Abstract
The current status of stability testing in Japan was investigated.　We identified ６６ new drug 
substances that had undergone stability testing in ２０１４.　Among these, there were ３２ were tested 
at ２５±２℃/６０±５％ relative humidity（RH）or ３０±２℃/６５±５％RH, １４ were tested at ５±３℃, and 
２ were tested at －２０±５℃ in long-term testing.　In the photostability testing, ２２ new drug substances 
were found to be stable optically and ２４ were unstable optically.　New drug substances that appeared 
unstable in photostability testing were stored in darkness.　From these results, the new drug 
substances approved according to the ICH guidelines in Japan in ２０１４ were found to perform 
adequately.
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原　著　論　文 
Introduction
Stability test results are an essential re-
quirement for New Drug Application.　The re-
quirement is discussed in the International 
Council on Harmonisation of Technical Re-
quirements for Registration of Pharmaceuti-
cals for Human Use（ICH）.１）　Revisions of the 
guidelines on stability testing have been per-
formed several times.
The guidelines for stability testing of new 
drug substances are listed for Table １.
ICHQ１A（R２）says that the stability 
data package for new drug substances or drug 
products is sufficient for a registration appli-
cation within the three regions of the Euro-
pean Union, Japan, and the United States.１）
ICHQ１B says that the intrinsic photosta-
bility characteristics of new drug substances 
and products should be evaluated to demon-
strate that light exposure does not cause un-
acceptable changes.２）
ICHQ１C is an annex to the ICHQ１A
（R２）and provides recommendations on what 
should be submitted regarding stability of 
new dosage forms by the original applicant, af-
ter the original submission for a new drug 
substance or product.３）
ICHQ１D provides recommendations on 
the application of bracketing and matrixing to 
stability studies.４）
ICHQ１E provides recommendations on 
how to use stability data generated in accor-
dance with the principles detailed in the ICH 
Q１A（R２）that can be used to propose retest 
periods or a shelf life in a registration appli- 
cation.５）　Additionally, this guideline describes 
when and how extrapolation can be considered 
when proposing a retest period for a drug sub-
stance or shelf life for a drug product that ex-
tends beyond the period covered by“available 
data from the stability studies under long-
term storage condition”.５）
In New Drug Application, long term stud-
ies and acceleration studies must be included 
in the stability testing according to the ICH 
Q１A（R２）.
Presently, we analyzed data on the stabil-
ity testing of ６６ drug substances that were ap-
proved in Japan in ２０１４ and verified whether 
these ICH guidelines were applied ade- 
quately.　Previously, we reported such analy-
ses in new drug products,７） but this report is 
first one regarding new drug substances.
MATERIALS AND METHODS
Drugs that were approved from January 
to December ２０１４ were surveyed.  The infor-
mation sources were the data summaries
（Module ２ of Common Technical Document
（CTD）in the present system）that were sub-
mitted by the applicants for New Drug Appli-
196
Hiroaki NAGAOKA, Takuma OHTSUBO, Tomohiro KISHI, Yuya DEGUCHI, Hiromi TAKANO OHMURO and Megumi HAMANO NAGAOKA
Table １　The guidelines for stability testing for new drug substances
AbbreviationName of Guideline
ICHQ１A（R２）Stability Testing of New Drug Substances and Products
ICHQ１BStability Testing: Photostability Testing of New Drug Substances and Products,
ICHQ１CStability Testing for New Dosage Form
ICHQ１DBracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
ICHQ１EEvaluation of Stability Data,
cations and the approval documents that 
described specifications and test methods of 
drug substances.　This information, espe-
cially the quality section, is not all publicly 
available, although Module ２ of the CTD and 
review reports available on the internet.６）　
Therefore, we did not disclose the individual 
substances’ name.
RESULTS AND DISCUSSION
Classification  of  Approved  Drugs  by 
Stability Testing
There were １３１ new drugs that were ap-
proved from January to December ２０１４, ex-
cluding antiseptics for medical devices, in vivo 
diagnostics, and generic drugs.
At first, we classified the drugs as those 
that underwent stability testing and those 
that did not.　The １３１ new drugs consisted of 
６６ drugs that did undergo stability testing 
and ６５ that did not（Fig. １）.
Because ６６ bulk drugs for which the sta-
bility test was not carried out were drugs with 
new administration routes or drugs with new 
indications or new dosage and administration, 
which is the so-called approval matter partial 
change application, they were not imposed on 
stability test.　Therefore, they do not have a 
description of a stability test.
We investigated further details of the ６６ 
new drug substances as shown in the follow-
ing sections.
Long-term Testing and Accelerated Testing
According to ICHQ１A（R２）,１） long-term 
testing for general new drug substances is per-
formed at ２５±２℃/６０±５％ relative humidity
（RH）or ３０±２℃/６５±５％RH.　 Accelerated 
testing for general new drug substances is per-
formed at ４０±２℃/７５±５％RH.　In the case 
of drug substances intended for storage in a 
refrigerator, long-term testing is performed 
at ５±３℃, and accelerated testing is performed 
at ２５±２℃/６０±５％RH.　In the case of drug 
substances intended for storage in a freezer, 
long-term testing is performed at －２０±５℃.　
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Fig. 1　Classification of New Drug Substances according to whether or not they 
　　　 underwent stability testing
Additionally, long term-testing for drug sub-
stances intended for storage at －２０℃ is 
treated on a case-by-case basis.
Long-term testing was performed for ３２ 
new drug substances at ２５±２℃/６０±５％RH 
or ３０±２℃/６５±５％RH, for １４ at ５±３℃, for 
２ at －２０±５℃, for ８ at other temperatures, 
and １０ for unknown temperatures（Fig. ２）.
Among these new drug substances, ２０ 
had shelf life or re-test period of ＞３６ months, 
１ had shelf life or re-test period of ３０ months, 
１９ had shelf life or re-test periods of ２４ 
months, ５ had shelf life or re-test period of １８ 
months, １ had shelf life or re-test period of １５ 
months, ５ had shelf life or re-test period of １２ 
months, １ had shelf life or re-test period of ６ 
months, and １４ had shelf life or re-test period 
that was unknown（Fig. ３）.
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Fig. ３　Specifications according to shelf life or re-test period
Fig. ２　Specifications of storage temperatures used in long term testing
There were １７ new drug substances that 
applied ICHQ１E５） and postponed the expira-
tion date（Fig. ４）.
Extrapolation to extend the retest period 
or shelf life beyond the period covered by long-
term data can be proposed in the application, 
particularly if no significant change is ob-
served under the accelerated condition.　The 
proposed retest period or shelf life can be up to 
twice, but should not be more than １２ months 
beyond, the period covered by long-term 
data.　As for Q１E application items, a long-
term testing of １２２４ months was carried out, 
thus we think that shelf life or re-test period 
of new drug substances are set adequately.
Accelerated testing was performed for all 
new drug substances（data not shown）.
From results of a long- term testing and 
accelerated testing, we think that shelf life or 
re-test period of new drug substances are set 
adequately.
Photostability Testing
According to ICHQ１B,２） photostability 
testing consists of two parts for drug 
substances: forced degradation testing and 
confirmatory testing.　The purpose of forced 
degradation testing is to evaluate the overall 
photostability of the material for methods de-
velopment purposes and/or degradation path-
way elucidation.　In these forced degradation 
studies, a variety of exposure conditions are 
used.　Decomposition products are sometimes 
observed that are unlikely to be formed under 
the conditions used for confirmatory studies 
under forcing conditions.　This information is 
useful in developing and validating analytical 
methods.　On the other hand, confirmatory 
studies are conducted to provide the informa-
tion necessary for packaging and labeling.
Twenty-two new drug substances were 
stable optically and ２４ were unstable optically
（Fig. ５）.　New drug substances that appeared 
unstable in photostability testing were stored 
in darkness.　Thus, we believe the storage con-
ditions are appropriate.
In conclusion, our review described ６６ new 
drug substances approved in Japan in ２０１４ 
that were based on ICH guidelines, all of 
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Fig. ４　The number of ICHQ１E applications
which performed adequately.
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Fig. ５　Itemization of photostability testing
